|
Synonyms: beta-nerve growth factor | beta-NGF | Oxervate® | Sentinel®
NGF is an approved drug (EMA (2017), FDA (2018))
Compound class:
Endogenous peptide in human, mouse or rat
Comment: Recombinant NGF (cenegermin, also known as cenegermin-bkbj) is used clinically as a peripherally selective agonist of TrkA and LNGFR. Note that the recombinant peptide is two amino acids shorter than the endogenous peptide, with the carboxy-terminal RA (Arg-Ala) removed.
Species: Human
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| No information available. |
Summary of Clinical Use  |
| Recombinant NGF (cenegermin) is EMA and FDA approved as a topically administered drug for the treament of neurotrophic keratitis. |
| Mechanism Of Action and Pharmacodynamic Effects |
| Cenegermin helps restore some of the normal ocular damage-repair and healing processes that are defective in patients with neurotrophic keratitis (NK). This is effective because NK patients often have abnormally low levels of growth factors that are supplied from the trigeminal nerve and which are essential for the growth and survival of the cells of the cornea. |
| External links |
|
For extended ADME data see the following: European Medicines Agency (EMA) |
